BIOX logo

Bioceres Crop Solutions (BIOX) News & Sentiment

Bioceres Is Approaching Distressed Prices, But I Remain On The Sidelines
Bioceres Is Approaching Distressed Prices, But I Remain On The Sidelines
Bioceres Is Approaching Distressed Prices, But I Remain On The Sidelines
BIOX
seekingalpha.comFebruary 13, 2025

Bioceres Crop Solutions Corp. reported a disappointing Q2 2025 with revenues down 24%, driven by Argentina's economic crisis, despite improved international sales. BIOX stock is down 62% year-over-year, and I maintain a Hold rating due to concerns about the company's ability to turn around. The shift to a licensing model for HB4 technology and R&D cuts may improve short-term finances but pose long-term risks.

Bioceres Crop Solutions Corp. (BIOX) Q2 2025 Earnings Call Transcript
Bioceres Crop Solutions Corp. (BIOX) Q2 2025 Earnings Call Transcript
Bioceres Crop Solutions Corp. (BIOX) Q2 2025 Earnings Call Transcript
BIOX
seekingalpha.comFebruary 12, 2025

Bioceres Crop Solutions Corp. (BIOX) Q2 2025 Earnings Call Transcript

Bioceres Crop Solutions Reports Fiscal Second Quarter 2025 Financial and Operational Results
Bioceres Crop Solutions Reports Fiscal Second Quarter 2025 Financial and Operational Results
Bioceres Crop Solutions Reports Fiscal Second Quarter 2025 Financial and Operational Results
BIOX
businesswire.comFebruary 11, 2025

ROSARIO, Argentina--(BUSINESS WIRE)--Bioceres Crop Solutions Corp. (Bioceres) (NASDAQ: BIOX), a leader in the development and commercialization of productivity solutions designed to regenerate agricultural ecosystems while making crops more resilient to climate change, announced financial results for the fiscal second quarter ended December 31, 2024. Financial results are expressed in U.S. dollars and are presented in accordance with International Financial Reporting Standards. All comparisons.

Bioceres Crop Solutions Updates Second Fiscal Quarter 2025 Expectations
Bioceres Crop Solutions Updates Second Fiscal Quarter 2025 Expectations
Bioceres Crop Solutions Updates Second Fiscal Quarter 2025 Expectations
BIOX
businesswire.comFebruary 5, 2025

ROSARIO, Argentina--(BUSINESS WIRE)--Bioceres Crop Solutions Corp. (NASDAQ: BIOX) today provided preliminary revenues, gross profit and adjusted EBITDA for the fiscal second quarter, ended December 31, 2024. Second quarter revenues are expected to be approximately $105 million, with gross profit of $45 million and adjusted EBITDA of $15 million. These results reflect challenging conditions in Argentina, which remains a decisive market for the financial performance of the company in the first ha.

Bioceres Crop Solutions Corp. (BIOX) Q1 2025 Earnings Call Transcript
Bioceres Crop Solutions Corp. (BIOX) Q1 2025 Earnings Call Transcript
Bioceres Crop Solutions Corp. (BIOX) Q1 2025 Earnings Call Transcript
BIOX
seekingalpha.comNovember 12, 2024

Bioceres Crop Solutions Corp. (NASDAQ:BIOX ) Q1 2025 Earnings Conference Call November 12, 2024 8:30 AM ET Company Participants Paula Savanti – Head-Investor Relations Federico Trucco – Chief Executive Officer Enrique López Lecube – Chief Financial Officer Conference Call Participants Ben Klieve – Lake Street Capital Markets Kristen Owen – Oppenheimer Kemp Dolliver – Brookline Capital Markets Andrew Steinhardt – Canaccord Genuity Operator Good morning, ladies and gentlemen, and thank you for standing by. Welcome to the Bioceres Crop Solutions Fiscal First Quarter 2025 Financial and Operational Results Call.

Bioceres Crop Solutions Reports Fiscal First Quarter 2025 Financial and Operational Results
Bioceres Crop Solutions Reports Fiscal First Quarter 2025 Financial and Operational Results
Bioceres Crop Solutions Reports Fiscal First Quarter 2025 Financial and Operational Results
BIOX
businesswire.comNovember 11, 2024

ROSARIO, Argentina--(BUSINESS WIRE)--Bioceres Crop Solutions Corp. (Bioceres) (NASDAQ: BIOX), a leader in the development and commercialization of productivity solutions designed to regenerate agricultural ecosystems while making crops more resilient to climate change, announced financial results for the fiscal first quarter ended September 30, 2024. Financial results are expressed in U.S. dollars and are presented in accordance with International Financial Reporting Standards. All comparisons.

3 Bargain Stocks Under $20 With Major Growth Potential
3 Bargain Stocks Under $20 With Major Growth Potential
3 Bargain Stocks Under $20 With Major Growth Potential
BIOX
marketbeat.comSeptember 30, 2024

For retail investors, momentum and trends can be drivers of investment decisions and interest. The stocks that analysts and other investors are talking about most may hold a special appeal (although timing the market and ensuring that you buy in at an appropriate time are difficult challenges).

Bioceres' Q4 2024 Shows Challenges With HB4 Rollout, Still A Hold Despite Lower Stock Prices
Bioceres' Q4 2024 Shows Challenges With HB4 Rollout, Still A Hold Despite Lower Stock Prices
Bioceres' Q4 2024 Shows Challenges With HB4 Rollout, Still A Hold Despite Lower Stock Prices
BIOX
seekingalpha.comSeptember 17, 2024

Bioceres' 4Q24 results disappointed, with flat profitability and a 15% stock drop, driven by a bear market in agricultural commodities and commercialization challenges for HB4 products. The company's debt rose, particularly short term, with unclear maturity risks, and profitability challenges persisted despite top-line growth. Bioceres is shifting tactics for HB4, reducing the priority of its identity-protected program to manage working capital and focusing more on its bio solutions segment.

Endeavour Achieves Commercial Production at BIOX Expansion and Lafigué Growth Projects
Endeavour Achieves Commercial Production at BIOX Expansion and Lafigué Growth Projects
Endeavour Achieves Commercial Production at BIOX Expansion and Lafigué Growth Projects
BIOX
globenewswire.comSeptember 13, 2024

ENDEAVOUR ACHIEVES COMMERCIAL PRODUCTION AT BIOX EXPANSION AND LAFIGUÉ GROWTH PROJECTS HIGHLIGHTS: • Commercial production achieved on budget and on schedule at the Sabodala-Massawa BIOX Expansion and the Lafigué mine on 1 August 2024 • Organic growth phase completed improving the quality of the portfolio and underpinning the transition to a phase focused on free cash flow generation • BIOX Expansion achieved commercial production; operating with 94% plant availability at 80% of nameplate capacity, with average recoveries of above 72% during July and August • Lafigué mine achieved commercial production only one month after the first gold pour; operating with 87% plant availability at 72% of nameplate capacity, with average recoveries of above 95% during August • The Group remains on track to achieve its full-year production guidance with AISC near the top end of the guided range London , 13 September 2024  – Endeavour Mining plc (LSE:EDV, TSX:EDV, OTCQX:EDVMF) (“Endeavour”, the “Group” or the “Company”) is pleased to announce that it has achieved commercial production at both its Sabodala-Massawa BIOX Expansion in Senegal and at its Lafigué mine in Côte d'Ivoire, effective as of 1 August 2024. Both projects have been completed on budget and on schedule, with the full ramp up to nameplate capacity underway.

Bioceres Crop Solutions Corp. (BIOX) Q4 2024 Earnings Call Transcript
Bioceres Crop Solutions Corp. (BIOX) Q4 2024 Earnings Call Transcript
Bioceres Crop Solutions Corp. (BIOX) Q4 2024 Earnings Call Transcript
BIOX
seekingalpha.comSeptember 10, 2024

Bioceres Crop Solutions Corp. (NASDAQ:BIOX ) Q4 2024 Earnings Conference Call September 10, 2024 8:30 AM ET Company Participants Paula Savanti - Head of IR Federico Trucco - CEO Enrique Lopez Lecube - CFO Conference Call Participants Ben Klieve - Lake Street Capital Markets Kristen Owen - Oppenheimer Kemp Dolliver - Brookline Capital Markets Austin Moeller - Canaccord Scott Fortune - ROTH Capital Partners Operator Good morning. Welcome to today's Bioceres Crop Solutions, Fiscal Fourth Quarter and Full Year 2024 Financial Results Conference call.

  • 1(current)
  • 2
  • 1(current)
  • 2